Dai Chung

Prof. Dai Chung

UT Southwestern Medical Center

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Advances in Pediatrics
Verified
Journal Article
Closed access
NCNadja C. Colon
Nadja C. Colon
Dai ChungDai Chung
Dai Chung

1 August 2012 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
JQJingbo Qiao
Jingbo Qiao
PPPritha Paul
Pritha Paul
SLSora Lee
Sora Lee
LQLan Qiao
Lan Qiao
EJErlena Josifi
Erlena Josifi
Dai ChungDai Chung
Dai Chung

1 March 2017 in Surgery
Verified
Journal Article
Closed access
EREric J. Rellinger
Eric J. Rellinger
BCBrian T. Craig
Brian T. Craig
AAAlexandra L. Alvarez
Alexandra L. Alvarez
HDHaley L. Dusek
Haley L. Dusek
KKKwang W. Kim
Kwang W. Kim
Dai ChungDai Chung
Dai Chung

27 June 2013 in Surgery
Verified
Journal Article
Closed access
PDF file
JQJingbo Qiao
Jingbo Qiao
SLSora Lee
Sora Lee
PPPritha Paul
Pritha Paul
LTLauren Theiss
Lauren Theiss
JTJoshua Tiao
Joshua Tiao
Dai ChungDai Chung
Dai Chung

17 January 2019 in Children
Verified
Journal Article
Open access
PDF file
Kyle Van ArendonkKyle Van Arendonk
Kyle Van Arendonk
Dai ChungDai Chung
Dai Chung
Neuroblastoma, the most common extracranial solid tumor of childhood, has widely variable outcomes dependent on the specific biology of the tumor. In this review, current biologic principles that are used to stratify risk and guide treatment algorithms are discussed. The role for surgical resection in neuroblastoma is also reviewed, including the indications and timing of surgery within the greater treatment plan.

16 November 2012 in Oncotarget
Verified
Journal Article
Open access
PDF file
SLSora Lee
Sora Lee
JQJingbo Qiao
Jingbo Qiao
PPPritha Paul
Pritha Paul
KOKathleen L. O’connor
Kathleen L. O’connor
BEB. Mark Evers
B. Mark Evers
Dai ChungDai Chung
Dai Chung
Neuroblastomas express increased levels of gastrin-releasing peptide receptor (GRP-R). However, the exact molecular mechanisms involved in GRP-R-mediated cell signaling in neuroblastoma growth and metastasis are unknown. Here, we report that focal adhesion kinase (FAK), as a critical downstream target of GRP-R, is an important regulator of neuroblastoma tumorigenicity. We found that FAK expression correlates with GRP-R expression in human neuroblastoma sections and cell lines. GRP-R overexpression in SK-N-SH cells increased FAK, integrin α3 and β1 expressions and cell migration. These cells demonstrated flatter cell morphology with broad lamellae, in which intense FAK expression was localized to the leading edges of lamellipodia. Interestingly, FAK activation was, in part, dependent on integrin α3 and β1 expression. Conversely, GRP-R silencing decreased FAK as well as Mycn levels in BE(2)-C cells, which displayed a denser cellular morphology. Importantly, rescue experiments in GRP-R silenced BE(2)-C cells showed FAK overexpression significantly enhanced cell viability and soft agar colony formation; similarly, FAK overexpression in SK-N-SH cells also resulted in increased cell growth. These effects were reversed in FAK silenced BE(2)-C cells in vitro as well as in vivo. Moreover, we evaluated the effect of FAK inhibition in vivo. FAK inhibitor (Y15) suppressed GRP-induced neuroblastoma growth and metastasis. Our results indicate that FAK is a critical downstream regulator of GRP-R, which mediates tumorigenesis and metastasis in neuroblastoma.